Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian‑incorporated biopharmaceutical issuer listed in the United States. Aurinia files annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K, along with exhibits such as earnings releases and investor presentations.
Recent Form 8‑K filings referenced in the available data show how Aurinia uses current reports to furnish quarterly financial results, updates on its share repurchase plan and key clinical developments. For example, the company has filed 8‑Ks to furnish earnings releases for quarters ended March 31, June 30 and September 30, 2025, and to report positive Phase 1 results for aritinercept (AUR200), its dual BAFF and APRIL inhibitor. These filings often attach press releases and presentations as exhibits, providing additional context on revenue, net product sales of LUPKYNIS (voclosporin), license and collaboration revenue, and operating expenses.
Through its periodic reports, Aurinia discloses condensed consolidated balance sheets, statements of operations and cash flows, detailing items such as cash, investments, inventory, lease liabilities, deferred revenue and shareholders’ equity. Investors analyzing AUPH can use 10‑K and 10‑Q filings to review the company’s financial position, revenue composition between LUPKYNIS net product sales and collaboration income, and risk factor discussions related to its autoimmune disease focus.
On Stock Titan, these SEC filings are complemented by AI‑powered summaries that highlight the main points of lengthy documents, helping readers quickly identify changes in revenue, profitability, cash flows or capital allocation, such as the expansion of a share repurchase plan. Real‑time updates from EDGAR ensure that new Aurinia 10‑K, 10‑Q, 8‑K and related exhibits, as well as insider transaction reports on Form 4 when filed, are surfaced promptly with simplified explanations for easier review.